id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
dpc-3790	Apalla, Zoe; Zafiriou, Efterpi ; Zagkliverinou, Effimia ; Roussaki-Schulze, Angeliki-Viktoria ; Gidarokosta, Polyxeni ; Ntavari, Niki ; Sakellaropoulou, Stella ; Boziou, Maria ; Emvalomati, Anastasia ; Kyrmanidou, Eirini ; Lazaridou, Elizabeth 	Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety	2024	7	.pdf	application/pdf	4064	285	58	The most common adverse events in patients with alopecia areata treated with baricitinib and tofacitinib in our cohort Type of adverse event Percentage (%) Elevated liver enzymes and lipid elevation 4.7 Lipid elevation 9.5 COVID-19 infection • mild symptoms • moderate symptoms • serious symptoms • asymptomatic 35.7 19.0 9.5 2.3 4.7 Herpes zoster and herpes simplex 2.3 None 59.5 Safety Outcomes Twenty five out of 42 (59.5%) individuals experienced no adverse events (AE), whilst 17/42 (40.5%) reported at least 1 AE, during JAKi treatment. Epidemiologic and clinical characteristics of the patients included in the study Variables All patients (N = 42) Socio-demographic features Age, years, mean (SD) 39.52 (14.48) Time since first onset, years mean (SD) 8.28 (10.73) Sex Male, % (N) 40.47% (17/42) Sex Female, % (N) 59.52% (25/42)	cache/dpc-3790.pdf	txt/dpc-3790.txt